These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 1718651

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ, Wierzbinski B, Collins J, Magoun S, Chen IW, Ryo UY.
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE.
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ, Li TY, Yang XC, Jia N, Yang XL, Song HB.
    Genet Mol Res; 2016 Jun 03; 15(2):. PubMed ID: 27323113
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].
    Desoize B, Pourny C, Amico S, Larbre H, Jardillier JC.
    Bull Cancer; 1990 Jun 03; 77(12):1211-21. PubMed ID: 2081281
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K, Alfthan O, Ikonen T, Ruutu M, Rannikko S.
    Scand J Urol Nephrol; 1984 Jun 03; 18(3):181-5. PubMed ID: 6494827
    [Abstract] [Full Text] [Related]

  • 13. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N, Suzuki H, Yano M, Endo T, Takano M, Komaru A, Kawamura K, Sekita N, Imamoto T, Ichikawa T.
    Urology; 2010 Jun 03; 75(6):1446-51. PubMed ID: 20206975
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
    Barichello M, Gion M, Bonazza A, Delli Ponti US, Bolgan A, Contemori GP, Barioli P, Capitanio G, Pecori B, Omacini S.
    Eur Urol; 1995 Jun 03; 27(4):295-300. PubMed ID: 7544735
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
    Casetta G, Gamba P, Piana P, Pecchio F, Tizzani A.
    Minerva Urol Nefrol; 1995 Mar 03; 47(1):9-12. PubMed ID: 7570264
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
    Lorente JA, Valenzuela H, Morote J, Gelabert A.
    Eur J Nucl Med; 1999 Jun 03; 26(6):625-32. PubMed ID: 10369948
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.